Market Place
Sourcing Support
MBX Biosciences Announces Last Visit in MBX 1416 Ph 1 Trial
18 Nov 2024 //
GLOBENEWSWIRE
MBX Bioscience Reports Q3 2024 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
MBX Biosciences to Attend November Investor Conferences
28 Oct 2024 //
#N/A
MBX Biosciences Presents Ph 2 Trial Design At ASBMR Meeting
30 Sep 2024 //
GLOBENEWSWIRE
MBX Biosciences Closes Upsized Initial Public Offering
16 Sep 2024 //
GLOBENEWSWIRE
MBX Biosciences Announces Pricing of Initial Public Offering
12 Sep 2024 //
GLOBENEWSWIRE
MBX Biosciences seeks up to $482.5 mln valuation in US IPO
09 Sep 2024 //
REUTERS
MBX Files For IPO To Fund Phase 3 Of Yorvipath Challenger
26 Aug 2024 //
FIERCE BIOTECH
Peptide Biotech MBX Submits IPO Plans For Post-Labor Day Nasdaq Listing
26 Aug 2024 //
ENDPTS
MBX Biosciences Doses First Patient In Phase 2 Hypoparathyroidism Trial
12 Aug 2024 //
GLOBENEWSWIRE
MBX Biosciences Raises $63.5M In Series C Financing
05 Aug 2024 //
GLOBENEWSWIRE
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
25 Jun 2024 //
GLOBENEWSWIRE
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
05 Feb 2024 //
GLOBENEWSWIRE
MBX Biosciences to Participate in Oppenheimer 34th Annual Conference
31 Jan 2024 //
GLOBENEWSWIRE
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
GLOBENEWSWIRE
MBX Bio to Participate in Piper Sandler 35th Annual Healthcare Conference
15 Nov 2023 //
GLOBENEWSWIRE
MBX Announces Appointment of Michelle Graham as Chief Human Resources Officer
01 Nov 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
31 Oct 2023 //
GLOBENEWSWIRE
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109
16 Oct 2023 //
GLOBENEWSWIRE
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416
09 Oct 2023 //
GLOBENEWSWIRE
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109
03 Oct 2023 //
GLOBENEWSWIRE
MBX Bio Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109
11 Sep 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
29 Aug 2023 //
GLOBENEWSWIRE
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416
07 Aug 2023 //
GLOBENEWSWIRE
MBX Biosciences Appoints Steven J. Prestrelski as Chief Scientific Officer
10 Jul 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in Jefferies Healthcare Conference
24 May 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in May Investor Conferences
08 May 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
MBX Bio to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
24 Jan 2023 //
GLOBENEWSWIRE
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
MBX Biosciences Closes $115 Million Series B Financing
14 Nov 2022 //
GLOBENEWSWIRE
MBX Biosciences Advances Ph1 Trial of Long-Acting Parathyroid , MBX 2109
05 Oct 2022 //
GLOBENEWSWIRE
MBX Biosciences Receives ODD for Lead Candidate MBX 2109 for Hypoparathyroidism
26 Jul 2022 //
GLOBENEWSWIRE
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
11 Apr 2022 //
GLOBENEWSWIRE
